The Third Circuit Court of Appeals, In re Lipitor Antitrust Litigation. 868 F.3d 231. (3d Cir. 2017) and 855 F.3d 12 (6th Cir. 2017) and 855 F.3d 126 (3d Cir.) and ruled that the district court had wrongly dismissed claims for class action. The case involved the Hatch-Waxman Act claim that consumers made under the Hatch Act, which states that companies with patents on Lipitor or Effexor XR engaged monopolistic procurement and enforcement actions against generic producers in order to thwart competition. Since the claims are founded on antitrust law and not patent law they were ruled on by the Third Circuit Court of Appeals instead of being resolved in the Federal Circuit Court of Appeals.
For more detail please visit>>>
The Third Circuit ruled that the accusations of fraud in the procurement and enforcement of patents did not come from the law of patents. The court denied requests to transfer the Hatch-Waxman case to the Federal Circuit. 855 F.3d 126 and 133.4 (3d Cir. 2017. The purpose of the regulatory framework was to encourage generic drug competition, ensure security to the public and promote the production of generic medicines. The Drug Price Competition and Patent Term Restoration Act also called the Hatch-Waxman Act, was enacted by Congress to help encourage generic drug makers to contest patents that are weak.
Manufacturers of name-brand drugs have to submit an New Drug Application (under the Act) to FDA. Generic manufacturers can make an Abbreviated New Drug Application if the manufacturer of the original approves the application. This certificate will prove that the generic is not infringing the patents of the manufacturer who originally made it. Generics with the identical active ingredients as the brand name drug and are biologically identical to the drug may be filed without the same rigorous tests.
If the patent has expired or invalid, or isn’t infringed by generics, there is no violation of the patent. The FDA does not allow generics for a minimum of 30 months if the maker of the brand name product is not in agreement. The Abbreviated New Drug Application is submitted by the first generic manufacturer. This permits the first manufacturer of generics to produce the generic drug for six months prior to when any other manufacturer can launch their own version.
But, this system could result in the collusion of generic and name brand manufacturers. F.T.C. F.T.C. in F.T.C. F.T.C. Actavis, Inc.,133 S. Ct. 2223, 2227, 1856L. Ed. 2d 343 (2013). The Supreme Court ruled that payments made by patent holders to infringers through “reverse settlement agreements” are subject to antitrust lawsuits. A reverse settlement agreement permits the generic manufacturer to cease production of the product. This permits the brand to maintain the most expensive cost. Since the generic manufacturer gets the money to not compete and this results in an antitrust scheme.
The same thing consumers said was the case in the Third Circuit cases: Lipitor and Effexor XR manufacturers had paid generic companies to not compete with products of name brands. The Third Circuit ruled that antitrust claims were based on the law of competition, not patent law. Although patent law has to be examined however, the case doesn’t require transfer to a different court. This could cause additional delays. The appeals court decided that the evidence didn’t establish federal diversity jurisdiction, and ordered the trial court to determine whether the federal courts have jurisdiction. The trial court ruled against both the Lipitor and Effexor XR manufacturer’s complaints upon the remand.
The Third Circuit reversed again the district court, and decided that the Lipitor plaintiffs had filed the claim that businesses were guilty of violating illegal reverse payment settlement agreements. 868 F.3d 231 253, 258 and 258 (3d Cir. 2017. The alleged illegal reverse-payment settlement was concluded after Lipitor’s maker paid the generic manufacturer, which did not have a claim for damages. The antitrust law is in violation in the event that the patent holder and generic manufacturer are in agreement to block the competition. The problem is now solved.